EC Number   |
General Information |
Reference |
|---|
   3.4.24.56 | malfunction |
deficiency in IDE function is associated with Alzheimer's disease and type 2 diabetes mellitus pathology. IDE levels are decreased in type 2 diabetes mellitus. Regulation of IDE by PPARgamma and their roles in Alzheimer's disease and type 2 diabetes mellitus pathology |
707363 |
| 3.4.24.56 | malfunction |
enzyme downregulation impairs SHSY5Y cell proliferation and triggers cell death. Enzyme inhibition is accompanied by a decrease of the poly-ubiquitinated protein content and co-immunoprecipitates with proteasome and ubiquitin in SHSY5Y cells |
734222 |
| 3.4.24.56 | malfunction |
genetic variants in the insulin-degrading enzyme gene are associated with metabolic syndrome in Chinese elders, relationship between the IDE gene and the development of metabolis syndrome, overview |
709818 |
| 3.4.24.56 | malfunction |
hypocatabolism of the amyloid beta-protein by insulin-degrading enzyme is implicated in the pathogenesis of Alzheimer's disease |
710361 |
| 3.4.24.56 | malfunction |
IDE catalyzes the degradation of the monomeric forms of Alzheimer amyloid beta peptides, which is critical for preventing the progression of Alzheimer's disease, overview |
707526 |
| 3.4.24.56 | malfunction |
loss of enzyme function favors insulin resistance, a hallmark of diabetes mellitus type II. Down-regulation of the enzyme provokes reduction of tissue growth and sensitizes developmental timing and metabolism to high-sucrose diets |
734661 |
| 3.4.24.56 | malfunction |
reduced neuronal expression of insulin-degrading enzyme in the left and right dorsolateral prefrontal cortex, but not in other brain areas investigated, of haloperidol-treated patients or patients with chronic schizophrenia. Reduced cortical IDE expression might be part of the disturbed insulin signaling cascades found in schizophrenia. Furthermore, it might contribute to the altered metabolism of certain neuropeptides, IGF-I and IGF-II, betab-endorphin, in schizophrenia |
709705 |
| 3.4.24.56 | malfunction |
reduced neuronal expression of insulin-degrading enzyme in the left and right dorsolateral prefrontal cortex, but not in other brain areas investigated, of haloperidol-treated rats |
709705 |
| 3.4.24.56 | malfunction |
reduction of IDE expression diminishes the ability of natriuretic peptides ANP and BNP to stimulate natriuretic peptide receptor NPR-B |
719995 |
| 3.4.24.56 | malfunction |
susceptibility of Goto-Kakizaki rats to diabetes due to IDE polymorphisms |
710682 |
